Clinical Trials Logo

Dyslipidemias clinical trials

View clinical trials related to Dyslipidemias.

Filter by:

NCT ID: NCT05004558 Not yet recruiting - Obesity Clinical Trials

Effects of Remote-based Resistance Training on Cardiometabolic Risk Factors, Cognitive Function, and Quality of Life in Adults Living With Alzheimer's Disease and/or Related Dementias

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The investigators aim to study the effects of a 24-week remote-based resistance exercise training program on cardiovascular disease risk factors, cognitive function, and quality of life in older adults living with mild cognitive impairment or Alzheimer's Disease and/or a related dementia. Data for this study will be collected at the beginning, middle, and end of the resistance training program. Participants of this study will receive a baseline health-fitness assessment at the beginning of the study. Measurements of resting blood pressure, fasting blood glucose and lipids, waist and hip circumferences, height and weight, cognitive function and quality of life will be collected at the health-fitness assessment. Participants will then receive supervised remote-based resistance exercise training with Therabands, 3 days per week for 12 weeks before receiving a second 12-week health-fitness assessment in the middle of the intervention. Participants will then receive 12 additional weeks of supervised remote-based resistance exercise training with Therabands, 3 days per week for 12 weeks before receiving a third 24-week health fitness assessment at the end of the study.

NCT ID: NCT04861545 Not yet recruiting - Clinical trials for Cardiovascular Risk Factor

Meta-analyses of Soy Protein and Its Food Sources for Cholesterol Reduction

Start date: May 1, 2021
Phase:
Study type: Observational

Although soy protein has approved health claims in Canada and the US, and is recognized by major cardiovascular clinical practice guidelines for the reduction of cholesterol and risk of coronary heart disease (CHD), these claims are based almost exclusively on evidence from foods containing isolated soy protein (ISP). The role of other non-ISP food sources of soy protein (e.g Tofu, tempeh, edamame) in these effects is unclear. The role of food form and matrix (e.g soy beverage versus meat analogue) on the effects of ISP is also unclear. As national dietary guidelines and clinical practice guidelines for nutrition therapy shift from a focus on single nutrients to a focus on foods and dietary patterns, it is important to understand whether non-ISP food sources of soy protein and ISP food sources with different food matrices produce the same reductions in LDL-cholesterol and CHD risk. To strengthen the evidence-base for health claims and guidelines development, the investigators will conduct a systematic review and meta-analysis of randomized controlled trials of the effect of ISP and non-ISP food sources of soy protein on stablished lipid targets in individuals with and without dyslipidemia.

NCT ID: NCT04861376 Not yet recruiting - Dyslipidemias Clinical Trials

Pueraria Lobata and Pueraria Thomsonii for Mild Dyslipidemia

Start date: May 10, 2021
Phase: N/A
Study type: Interventional

Dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease. Maintaining normal levels of lipid indicators can significantly reduce the risk of atherosclerotic cardiovascular disease and mortality. Empirical evidence suggests that adherence to Pueraria lobata and Pueraria thomsonii is useful for improving dyslipidemia, but evidence from randomized controlled trials is lacking. This randomized, double-blind controlled trial is therefore designed to evaluate the efficacy and safety of Pueraria lobata and Pueraria thomsonii for dyslipidemia.

NCT ID: NCT04860063 Not yet recruiting - Metabolic Syndrome Clinical Trials

Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH.

BERMESyH
Start date: April 2021
Phase: Phase 3
Study type: Interventional

With current antiretroviral therapy, people living with HIV reach virological suppression faster, which in turn leads to a higher life expectancy. Nevertheless, this improved survival rate is not free of other comorbidities, such as metabolic syndrome, characterized by a decrease in glucose tolerance and an increase in insulin resistance. Berberine is an alkaloid that has proven beneficial effects on both glucose tolerance and insulin resistance, but has not been tested in people living with HIV under virological suppression. We hypothesize that berberine will improve inflammatory markers and metabolic profile in this population without significant interactions nor adverse effects.

NCT ID: NCT04772443 Not yet recruiting - Dyslipidemias Clinical Trials

Evaluate the Efficacy and Safety of DWJ1506 and DWJ1507

Start date: February 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of DWJ1506 and DWJ1507 in the patients with dyslipidemia.

NCT ID: NCT04603508 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia

Start date: March 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Berlim 25/10 association in the treatment of type 2 diabetes mellitus and dyslipidemia.

NCT ID: NCT04300764 Not yet recruiting - Obesity Clinical Trials

Gamification to Increase Mobility in the Hospital

Level Up
Start date: January 1, 2026
Phase: N/A
Study type: Interventional

Low mobility is a mediator for poor outcomes of hospital care. Wearable devices will be used and 2-way texting via patient smartphones to monitor patients' physical activity during hospitalization with and without gamification to improve patient adherence to existing guidance on recommended activity. After discharge, investigators will assess patient care utilization (SNF, inpatient vs home rehab, ED visits, readmission) and conduct validated surveys on patient function at 30 days after discharge.

NCT ID: NCT04185090 Not yet recruiting - Hypertension Clinical Trials

To Evaluate the Pharmacokinetic/Pharmacodynamic Interactions and Safety Between ID1801 and ID1803 in Healthy Male Adults

Start date: February 2020
Phase: Phase 1
Study type: Interventional

This study is designated to evaluate the pharmacokinetic interactions of valsartan, amlodipine besylate, rosuvastatin, and ezetimibe in healthy male volunteers.

NCT ID: NCT04164771 Not yet recruiting - Dyslipidemias Clinical Trials

Effect of Aerobic Training and Moringa Oleifera on Dyslipidemia and Cardiac Endurance

Start date: February 2020
Phase: N/A
Study type: Interventional

Aerobic training is essential for maintaining and improving physical performance and has a positive effect on physiological functions as well as anthropometric characteristics. It also has positive effect on cardiovascular health and carries a number of beneficial effects on the whole body functions and systems. Aerobic training can also decrease the risk of heart disease in the individual's life.The Moringa leaves are the rich source of minerals, vitamins and other essential phytochemicals. Moringa leave have found to be very effective in many disease particularly diabetic, blood pressure, dyslipidemia and cancer.

NCT ID: NCT04133129 Not yet recruiting - Obesity Clinical Trials

Effects of HIIT on Metabolic Syndrome

Start date: November 1, 2019
Phase: N/A
Study type: Interventional

The project aims to find out the differences between two different types of structured training interventions have on the lipid profile of persons with diagnosed dyslipidemia. Each training intervention will last for 12 weeks. Subjects participating in the project will undergo a series of tests before and after the training intervention which will allow us to make conclusions.